Frequency of and time to insulin use in diabetic patients receiving metformin (MF) and sulfonylurea (SU) combination therapy

被引：0
|
作者：
Pietri, G
Yin, DD
Lyu, RR
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A296 / A296
页数：1
相关论文
共 50 条
  • [31] Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy
    Yoshida, Masanori
    Asai, Masato
    Miyata, Misaki
    Ogawa, Koichiro
    Maeda, Harumi
    Oiso, Yutaka
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 96 (03) : E55 - E56
  • [32] Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    Russell-Jones, D.
    Vaag, A.
    Schmitz, O.
    Sethi, B. K.
    Lalic, N.
    Antic, S.
    Zdravkovic, M.
    Ravn, G. M.
    Simo, R.
    DIABETOLOGIA, 2009, 52 (10) : 2046 - 2055
  • [33] Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    D. Russell-Jones
    A. Vaag
    O. Schmitz
    B. K. Sethi
    N. Lalic
    S. Antic
    M. Zdravkovic
    G. M. Ravn
    R. Simó
    Diabetologia, 2009, 52 : 2046 - 2055
  • [34] Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients - Response to Rosenstock et al.
    Hamid, Zulekha
    Simmons, Debra L.
    DIABETES CARE, 2006, 29 (10) : 2331 - 2331
  • [35] Dual therapy with inhaled human insulin (Exubera®) as add-on to metformin (with stopping sulfonylurea) is better than triple therapy with rosiglitazone add-on to combination metformin and sulfonylurea in poorly controlled type 2 diabetes
    Rosenstock, Julio
    Gross, Jorge
    Eliaschewitz, Reddy
    Mitnick, Michael
    Lawrence, David
    Canovatchel, William
    Hollander, Priscilla
    DIABETES, 2008, 57 : A557 - A557
  • [36] Metformin (M), Sulfonylurea (SU), or Both as Background OAD Therapy for Insulin Glargine (IG): A Pooled Analysis of Treat-To-Target Trials
    Devries, J. Hans
    Barnett, Anthony H.
    Reid, Timothy
    Dain, Marie-Paule
    Landgraf, Wolfgang
    Vlajnic, Aleksandra
    Traylor, Louise
    Bergenstal, Richard M.
    DIABETES, 2013, 62 : A243 - A244
  • [37] Comparison between aspart and regular insulin in combination with metformin in Type 2 diabetic patients
    Rotella, CM
    Pala, L
    Dicembrini, I
    Mannucci, E
    DIABETOLOGIA, 2004, 47 : A266 - A267
  • [38] COMBINATION OF INSULIN AND SULFONYLUREA (SU) IN THE TREATMENT OF TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES WITH SECONDARY FAILURE OF SU THERAPY (SF) - LONG-TERM RESULTS
    LOTZ, N
    LADIK, T
    RUPP, P
    BACHMANN, W
    MEHNERT, H
    DIABETOLOGIA, 1987, 30 (07) : A551 - A551
  • [39] Intensive insulin therapy combined with metformin in obese type 2 diabetic patients
    Fritsche, A
    Schmülling, RM
    Häring, HU
    Stumvoll, M
    ACTA DIABETOLOGICA, 2000, 37 (01) : 13 - 18
  • [40] Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
    Rosenstock, J
    Sugimoto, D
    Strange, P
    Stewart, JA
    Soltes-Rak, E
    Dailey, G
    DIABETES CARE, 2006, 29 (03) : 554 - 559
12345